Ceftobiprole

[1]  K. Bush,et al.  A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Solomkin,et al.  Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria , 2007, Antimicrobial Agents and Chemotherapy.

[3]  Robin Patel,et al.  In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. , 2007, Diagnostic microbiology and infectious disease.

[4]  M. Page,et al.  Interactions of Ceftobiprole with β-Lactamases from Molecular Classes A to D , 2007, Antimicrobial Agents and Chemotherapy.

[5]  P. Lebecque,et al.  Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  S. Shapiro,et al.  Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin. , 2007, Diagnostic microbiology and infectious disease.

[7]  M. Page,et al.  Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae , 2007, Antimicrobial Agents and Chemotherapy.

[8]  G. Archer,et al.  Identification and Phenotypic Characterization of a β-Lactam-Dependent, Methicillin-Resistant Staphylococcus aureus Strain , 2007, Antimicrobial Agents and Chemotherapy.

[9]  C. Arias,et al.  Time-Kill and Synergism Studies of Ceftobiprole against Enterococcus faecalis, Including β-Lactamase-Producing and Vancomycin-Resistant Isolates , 2007, Antimicrobial Agents and Chemotherapy.

[10]  K. Bush,et al.  Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects , 2007, Antimicrobial Agents and Chemotherapy.

[11]  K. Bush,et al.  Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy , 2007 .

[12]  R. Hall,et al.  Infectious Diseases: Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant Staphylococcus aureus , 2007, The Annals of pharmacotherapy.

[13]  R. Drew.  Emerging Options for Treatment of Invasive, Multidrug‐Resistant Staphylococcus aureus Infections , 2007, Pharmacotherapy.

[14]  H. Giamarellou,et al.  Investigational treatments for postoperative surgical site infections , 2007, Expert opinion on investigational drugs.

[15]  H. Boucher,et al.  New agents for Staphylococcus aureus endocarditis , 2006, Current opinion in infectious diseases.

[16]  P. Appelbaum,et al.  Postantibiotic Effect of Ceftobiprole against 12 Gram-Positive Organisms , 2006, Antimicrobial Agents and Chemotherapy.

[17]  D. Paterson.  Clinical experience with recently approved antibiotics. , 2006, Current opinion in pharmacology.

[18]  M. Page.  Anti-MRSA β-lactams in development , 2006 .

[19]  E. Goldstein,et al.  In Vitro Activity of Ceftobiprole against Aerobic and Anaerobic Strains Isolated from Diabetic Foot Infections , 2006, Antimicrobial Agents and Chemotherapy.

[20]  M. Struelens,et al.  In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian Hospitals , 2006, Antimicrobial Agents and Chemotherapy.

[21]  Robin Patel,et al.  Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. , 2006, Diagnostic microbiology and infectious disease.

[22]  K. Bush,et al.  Activities of Ceftobiprole and Other β-Lactams against Streptococcus pneumoniae Clinical Isolates from the United States with Defined Substitutions in Penicillin-Binding Proteins PBP 1a, PBP 2b, and PBP 2x , 2006, Antimicrobial Agents and Chemotherapy.

[23]  S. Shapiro,et al.  Activities of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis , 2006, Antimicrobial Agents and Chemotherapy.

[24]  S. Shapiro,et al.  Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin , 2005, Antimicrobial Agents and Chemotherapy.

[25]  J. Bosso.  The Antimicrobial Armamentarium: Evaluating Current and Future Treatment Options , 2005, Pharmacotherapy.

[26]  A. Friedrich,et al.  Comparative In Vitro Activity of Ceftobiprole against Staphylococci Displaying Normal and Small-Colony Variant Phenotypes , 2005, Antimicrobial Agents and Chemotherapy.

[27]  H. Lode,et al.  New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient , 2005, Current opinion in critical care.

[28]  M. Jacobs,et al.  Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. , 2005, Current opinion in microbiology.

[29]  J. Schrenzel,et al.  Intensive Therapy with Ceftobiprole Medocaril of Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[30]  H. Hoffman-Roberts,et al.  Investigational new drugs for the treatment of resistant pneumococcal infections , 2005, Expert opinion on investigational drugs.

[31]  S. Shapiro,et al.  Antipneumococcal Activity of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin , 2005, Antimicrobial Agents and Chemotherapy.

[32]  H. Chambers.  Evaluation of Ceftobiprole in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[33]  M. Kurowski,et al.  Ertapenem Pharmacokinetics and Impact on Intestinal Microflora, in Comparison to Those of Ceftriaxone, after Multiple Dosing in Male and Female Volunteers , 2004, Antimicrobial Agents and Chemotherapy.

[34]  Ronald N. Jones,et al.  Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. , 2004, Diagnostic microbiology and infectious disease.

[35]  R. Jones,et al.  Quality Control Guidelines for BAL9141 (Ro 63-9141), an Investigational Cephalosporin, When Reference MIC and Standardized Disk Diffusion Susceptibility Test Methods Are Used , 2004, Journal of Clinical Microbiology.

[36]  P. Kovacs,et al.  Single-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy Volunteers , 2004, Antimicrobial Agents and Chemotherapy.

[37]  A. Schmitt-Hoffmann,et al.  Use of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141 , 2004, Antimicrobial Agents and Chemotherapy.

[38]  J. Mohler,et al.  Efficacy of BAL5788, a Prodrug of Cephalosporin BAL9141, in a Mouse Model of Acute Pneumococcal Pneumonia , 2004, Antimicrobial Agents and Chemotherapy.

[39]  Ronald N. Jones,et al.  Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[40]  V. Tam,et al.  Pharmacokinetics and Pharmacodynamics of Cefepime in Patients with Various Degrees of Renal Function , 2003, Antimicrobial Agents and Chemotherapy.

[41]  J. Shimada,et al.  In Vitro Activity of S-3578, a New Broad-Spectrum Cephalosporin Active against Methicillin-Resistant Staphylococci , 2003, Antimicrobial Agents and Chemotherapy.

[42]  G. Amsden,et al.  Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. , 2002, The Journal of antimicrobial chemotherapy.

[43]  Ronald N. Jones,et al.  In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. , 2002, The Journal of antimicrobial chemotherapy.

[44]  K. Bowker,et al.  BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. , 2002, The Journal of antimicrobial chemotherapy.

[45]  R. Zbinden,et al.  In Vitro Activities of BAL9141, a Novel Broad-Spectrum Pyrrolidinone Cephalosporin, against Gram-Negative Nonfermenters , 2002, Antimicrobial Agents and Chemotherapy.

[46]  P. Moreillon,et al.  BAL9141, a Novel Extended-Spectrum Cephalosporin Active against Methicillin-Resistant Staphylococcus aureus in Treatment of Experimental Endocarditis , 2002, Antimicrobial Agents and Chemotherapy.

[47]  C. Gomersall,et al.  The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. , 2001, The Journal of antimicrobial chemotherapy.

[48]  M. Page,et al.  In Vitro and In Vivo Properties of Ro 63-9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococci , 2001, Antimicrobial Agents and Chemotherapy.

[49]  J. Garrelts,et al.  The Pharmacokinetics, Safety, and Tolerance of Cefepime Administered as an Intravenous Bolus or as a Rapid Infusion , 1999, The Annals of pharmacotherapy.

[50]  J. T. ter Maaten,et al.  Pharmacokinetics of cefepime in patients with respiratory tract infections , 1990, Antimicrobial Agents and Chemotherapy.

[51]  D. Weidler,et al.  Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses , 1990, Antimicrobial Agents and Chemotherapy.

[52]  H. Simmen,et al.  Comparative Multiple-Dose Pharmacokinetics of Cefotaxime, Moxalactam, and Ceftazidime , 1981, Antimicrobial Agents and Chemotherapy.

[53]  P. Appelbaum.  MRSA--the tip of the iceberg. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[54]  H. Chambers.  Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[55]  D. Livermore.  Can β‐lactams be re‐engineered to beat MRSA? , 2006 .

[56]  Robin Patel,et al.  In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. , 2004, Diagnostic microbiology and infectious disease.

[57]  Jerome J. Schentag,et al.  Clinical Use of Ceftriaxone , 2001, Clinical pharmacokinetics.

[58]  D. Burgess,et al.  Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. , 2000, Clinical therapeutics.